RxDoctor Payments Data

John Warren

Internal Medicine · Tuscaloosa, ALNPI 1013120104

Payments from drug & device makers

$245in general payments, 2019–2025

Across 14 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$58
  • Genentech USA, Inc.$39
  • Abbott$35
  • Exact Sciences$32
  • Lombart Brothers, Inc.$19
  • Lundbeck LLC$18
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$245100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer3$58
Genentech USA, Inc.2$39
Abbott2$35
Exact Sciences2$32
Lombart Brothers, Inc.1$19
Lundbeck LLC1$18
Lilly USA, LLC1$16
Novo Nordisk1$15
Novartis1$14

How this compares

$245 in reported general payments places this provider in the 40th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$405,443
Medicare patients
560
Services billed
25,732

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban621$383,169
MounjaroTirzepatide204$219,009
OzempicSemaglutide148$157,798
TrulicityDulaglutide156$155,160
JardianceEmpagliflozin225$153,080
XifaxanRifaximin36$89,915
NuplazidPimavanserin Tartrate36$88,778
XareltoRivaroxaban100$87,323
Trelegy ElliptaFluticasone/Umeclidin/Vilanter78$55,410
MyrbetriqMirabegron64$44,900
Janumet XrSitagliptin Phos/Metformin Hcl75$43,310
LinzessLinaclotide34$34,948
JanuviaSitagliptin Phosphate27$31,794
AptiomEslicarbazepine Acetate24$30,390
JanumetSitagliptin Phos/Metformin Hcl55$30,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$58$383,169621 claims
Lilly USA, LLCMounjaro, Trulicity$16$374,170360 claims
Novo NordiskOzempic, Rybelsus$15$169,108160 claims
NovartisEntresto$14$22,02129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Tuscaloosa

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →